Document |
Document Title |
WO/2005/009928A2 |
The present disclosure provides methods of synthesizing alkylating agents and methods of use.
|
WO/2005/007615A1 |
Disclosed are 2-(amino or substituted amino)-5-(substituted oxymethyl)-phenol compounds according to the Formula (I). Also, compositions for the oxidative dyeing of keratin fibers, comprising a medium suitable for dyeing and a compound o...
|
WO/2005/005356A2 |
Method of preparing an enantiomerically enriched compound of formula (II) comprising enantioselective hydrogenation of a compound of general formula (I): where W, X and Z have the meanings indicated in the description, to give a compound...
|
WO/2005/000786A1 |
An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethan...
|
WO/2005/000795A2 |
This invention relates to aniline derived non-steroidal compounds that are or are believed to be modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of suc...
|
WO/2004/113268A1 |
The present invention relates to a process for preparing an ethanolamine having an improved colour quality. The process comprises contacting ethanolamine with an activated carbon free of one or more metals chosen from Re, Ru, Rh, Pd, Os,...
|
WO/2004/113295A1 |
In one embodiment, the present application relates to a process of making a compound of Formula (I); and to certain intermediate compounds that are made within the process of making the compound Formula (I).
|
WO/2004/110978A2 |
This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.
|
WO/2004/108657A1 |
Disclosed is a preparation method of valienamine using solid catalysts. The valienamine, which has strong inhibiting activity, is prepared by selective hydrolysis of acarbose and acarbose derivatives, validamycin and validamycin derivati...
|
WO/2004/108658A1 |
The invention relates to a method for the dehydration of substituted 1-amino-3-aryl-butane-3-oil compounds for the production of substituted 3-aryl-butyl-amine compounds.
|
WO/2004/105692A2 |
The present invention relates to smooth muscle spasmolytic agents, pharmaceutical compositions containing them and method of using said compounds and compositions for the treatment of urinary incontinence, and other smooth muscle contrac...
|
WO/2004/106279A2 |
The invention provides a novel β2 adrenergic receptor agonist in crystalline salt form. The invention also provides pharmaceutical compositions comprising the novel β2 adrenergic receptor agonist in crystalline salt form, formulations ...
|
WO/2004/105697A2 |
Cationic lipid compositions are provided that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types. Methods for using the compositions are also provided.
|
WO/2004/101502A1 |
This invention relates to a novel class of linear polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for their production. The compounds may be obtained by cultivation of Streptomyces melanospora...
|
WO/2004/101493A1 |
An acid addition salt of a carbasugar amine derivative represented by the following general formula (1): wherein R1 and R2 each independently represents hydrogen or an alkyl, alkenyl, alkynyl, acyl, aryl, or aralkyl group optionally havi...
|
WO/2004/096951A1 |
Compositions and methods for inhibiting polymerization of ethylenically unsaturated monomers are provided. The compositions include a water-soluble phenylenediamine composition.
|
WO/2004/096740A2 |
A process for preparing (+)-p-mentha-2,8-diene-1-ol comprising reacting (+)-limonene oxide with at least one amine in the presence of at least one Lewis acid to form amine adduct intermediates. The amine adduct is then oxidized to form a...
|
WO/2004/093800A2 |
Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed.
|
WO/2004/091607A1 |
Novel quaternary ammonium compounds of the formula and any stereoisomers thereof, wherein R1, R2 R3, R4, R5, R6, R7, and X- are defined herein. The compounds are useful as medicaments for treatment of treatment of asthma, a group of brea...
|
WO/2004/089281A2 |
The present invention relates to novel polyphorms of tolterodine tartrate, to processes for their preparation and to phrmaceutical compositions containing them.
|
WO/2004/089871A1 |
A method for producing trans-2-[(&agr -methylbenzyl)amino] cyclopentanol being highly pure as a diastereoisomer, which comprises reacting a mixture of two diastereoisomers of trans-2-[(&agr -methylbenzyl)amino]cyclopentanol represented b...
|
WO/2004/090070A1 |
An antioxidant is disclosed which is composed of an aromatic hydroxyamine derivative having a structure expressed by the general formula (1) (wherein R1-R3 represent hydrogen atoms or alkyl groups, X represents a hydrogen atom or an OH g...
|
WO/2004/087628A1 |
This invention relates to a process of asymmerically alkynating ketones or ketoimines by asymmerical addition of terminal alkynes to trifluoromethyl ketones or trifluoromethyl ketoimines in the presence of copper or zinc salt and a kind ...
|
WO/2004/082651A1 |
A method and composition is provided for managing in-grown hair which involves applying to those areas malonic acid or a salt thereof in a carrier. The method and composition allows for comfortable shaving of skin by minimizing the probl...
|
WO/2004/080934A2 |
A process for the preparation of a compound of formula (I), wherein R1, and R2 are ortho or para substituents, independently selected from the group consisting of hydrogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C7-C9 aralkoxy, C2-C7 alkan...
|
WO/2004/080377A2 |
This invention relates to compounds of the general formula (I) useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.
|
WO/2004/078700A1 |
The invention relates to 3,3-diarylpropylamines derivatives and processes for producing them. More particularly, it relates to the preparation of pure tolterodine or a pharmaceutically acceptable salt thereof and pharmaceutical compositi...
|
WO/2004/078701A1 |
Compounds capable of giving novel materials which are excellent in heat resistance, mechanical characteristics, electrical characteristics, physical characteristics and so on and useful as interlayer dielectrics or protection films of se...
|
WO2004017920B1 |
Novel biphenyl and biphenyl-like cannabinoid compounds are presented. These compounds, when administered in a therapeutically effective amount to an individual or animal, result in a sufficiently high level of that compound in the indivi...
|
WO/2004/069786A1 |
Ligands characterized by being represented by the general formula (1): R1R2N-Q1-X-Q2-NR3R4 wherein R1, R2, R3 and R4 are each independently a group represented by the general formula (2): (2) (wherein Q3 is optionally substituted alkylen...
|
WO/2004/065401A1 |
This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains...
|
WO/2004/065349A1 |
The invention relates to the compounds of 1-phenyl-2-aminomethyl naphthalene derivatives of the general formula (1), and to methods for their production. 1-Phenyl-2-aminomethyl naphthalenes have antitumoral properties in cell culture mod...
|
WO/2004/063175A1 |
The invention disclosed in this application relates to an improved process for the preparation of the oxazolidinone of formula (I) It comprises (i) Preparing the 4-nitro-(S)-phenylalaninol of formula (IV) by conventional methods. (ii) Re...
|
WO/2004/060882A1 |
Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein Ar1, Ar2, R1, R2, n and X are as defined in the specificationas well as salts and pharmaceutical compositions including the compounds are prepared. They are us...
|
WO/2004/058682A1 |
Compounds represented by the general formula (I), salts thereof, and hydrates of both: (I) wherein T is a single bond, optionally substituted C1-4 alkylene, or the like; the symbols &dot &dot &dot &dot &dot &dot are each a single bond or...
|
WO/2004/054963A1 |
The present invention relates to sphingolipid derivatives modified by polyethylene glycol which have superior stability and solubility to conventional sphingolipid derivatives and remarkably reduced toxicity, wherein the sphingolipid is ...
|
WO/2004/052835A1 |
Levalbuterol L-tartare affords crystals possessing properties desirable for use in a metered dose inhaler.
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
WO/2004/046083A1 |
The invention relates to compounds of general formula (I), where the groups R1, R2, R3 and R4 can have the meanings given in the claims and description, method for production and use thereof as medicament, in particular for the treatment...
|
WO/2004/043921A1 |
A novel, improved, and general process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines is disclosed in the present invention. 4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine is a well-known intermediate in making ...
|
WO/2004/041226A1 |
Disclosed are compounds of formula (I) and agents for dyeing keratin fibers, especially hair, which contain said 4-amino-biphenyl-3-ol-derivatives of general formula (I). The following applies: R1 and R2 independently represent hydrogen,...
|
WO/2004/037771A1 |
The compound of formula (III), optionally its alkaline salt, is reacted with a compound of formula VII, wherein X is a leaving group, resulting in (S)-rivastigmine of formula II, which is then optionally converted into (S)-rivastigmine h...
|
WO/2004/037767A1 |
The invention relates to an improved method for producing levosalbutamol or the pharmacologically acceptable salts thereof on an industrial scale by using asymmetric hydration as a key step and, optionally, a special sequence of successi...
|
WO/2004/035521A1 |
Compounds of Formula (1), wherein R1 is hydrogen; C1-C18alkyl; trifluoromethyl; C3-C8cycloalkyl; phenyl-C1-C5alkyl; phenyl-C1-C5alkoxy; mono- or di-N-C1-C5alkylamino-C1-C5alkyl; amino-di-N-C1-C5alkylamino-C1-C5alkyl; C1-C5alkoxy-C1-C5alk...
|
WO/2004/029004A1 |
The invention relates to the use of an ionic liquid as a matrix liquid for organic synthesis in a homogeneous phase on a soluble medium, said ionic liquid being present in the form of a liquid or solid at room temperature, having formula...
|
WO/2004/026815A2 |
The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)-, -C(S)-, -C(O)-NR10-, -C(S)-NR11-, -C(N-CN)-NR12-, -...
|
WO/2004/022522A1 |
The invention relates to a method for the production of optically active 2-amino-, 2 chloro-, 2-hydroxy- or 2-alkoxy-1-alkanoles by catalytic hydrogenation of corresponding optically active 2-amino-, -chloro-, 2-hydroxy- and 2-alkoxy car...
|
WO/2004/020389A1 |
The invention relates to methods for the enantioselective production of amino alcohols of formula (I), wherein R1, R2 and n have the meaning cited in the description.
|
WO/2004/018402A1 |
A solvent-soluble oligomer or polymer comprising an open-chain condensate of an aldehyde of formula R - CHO (I). Wherein R is a substituted or unsubstituted hydrocarbon group, for example, an alkyl group, or a fluorinated alkyl group, ...
|
WO/2004/013069A1 |
The present invention relates to the field of organic synthesis and more particularly to a new process for the optical resolution of a precursor of sclareolide. Said process is characterized by the reaction of [(1RS,2RS,4aSR,8aSR)-2-hydr...
|